Literature DB >> 3488195

Epidemiological and bacteriological findings on Branhamella catarrhalis respiratory infections in The Netherlands.

B I Davies, F P Maesen.   

Abstract

The frequency of isolation of Branhamella catarrhalis from sputum in a laboratory in the southern part of the Netherlands is reviewed; at present 23% of positive cultures contain these organisms. Seasonal variations include a considerable reduction in frequency of isolation in the summer months. The possible role of heavy industry and air pollution is briefly discussed. Evidence for the direct pathogenicity of B. catarrhalis is presented, and although this may be considered as only circumstantial it is still convincing, particularly in acute otitis media and in acute purulent exacerbations of chronic respiratory disease. The possibility of indirect pathogenicity through beta-lactamase production is discussed as is the evidence obtained by the use of several new antimicrobial agents which were subsequently shown to have been inappropriate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488195     DOI: 10.2165/00003495-198600313-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  27 in total

1.  Studies on the treatment with antibacterial drugs of acute and chronic mucopurulent bronchitis caused by Hemophilus influenzae.

Authors:  J MULDER; W R O GOSLINGS; M C VAN DER PLAS; P L CARDOZO
Journal:  Acta Med Scand       Date:  1952-05-10

2.  [Branhamella catarrhalis in infectious pathology of the respiratory tract].

Authors:  A Le Faou; A Rio
Journal:  Presse Med       Date:  1983-09-24       Impact factor: 1.228

3.  beta-Lactamase-producing Branhamella catarrhalis causing otitis media in children.

Authors:  A L Kovatch; E R Wald; R H Michaels
Journal:  J Pediatr       Date:  1983-02       Impact factor: 4.406

4.  Pathogenicity of and beta-lactamase production by Branhamella (Neisseria) catarrhalis.

Authors:  A Percival; J E Corkill; J Rowlands; R B Sykes
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321

5.  Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture.

Authors:  G Ninane; J Joly; M Kraytman
Journal:  Br Med J       Date:  1978-02-04

6.  Pefloxacin in acute exacerbations of chronic bronchitis.

Authors:  F P Maesen; B I Davies; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

7.  Emergence of beta-lactamase-producing strains of Branhamella catarrhalis as important agents of acute otitis media.

Authors:  P A Shurin; C D Marchant; C H Kim; G F Van Hare; C E Johnson; M A Tutihasi; L J Knapp
Journal:  Pediatr Infect Dis       Date:  1983 Jan-Feb

8.  Is treatment of acute exacerbations of chronic bronchitis with intramuscular mezlocillin justifiable?

Authors:  F P Maesen; B I Davies; J Brouwers; T Salemans
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

9.  Aztreonam in patients with acute purulent exacerbations of chronic bronchitis: failure to prevent emergence of pneumococcal infections.

Authors:  B I Davies; F P Maesen; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1985-03       Impact factor: 5.790

10.  Latamoxef (moxalactam) in acute exacerbations of chronic bronchitis.

Authors:  F P Maesen; B I Davies; J Brouwers; T Salemans; M Nelissen-Wamper; H Debruyne
Journal:  J Antimicrob Chemother       Date:  1983-02       Impact factor: 5.790

View more
  13 in total

Review 1.  Lung infections. 2. Branhamella catarrhalis: epidemiological and clinical aspects of a human respiratory tract pathogen.

Authors:  T F Murphy
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

Review 2.  Antimicrobial susceptibility testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae.

Authors:  G V Doern; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

3.  The use of quinolones in respiratory tract infections.

Authors:  F P Maesen; B I Davies; W H Geraedts; C Baur
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 4.  Branhamella catarrhalis: an organism gaining respect as a pathogen.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

5.  BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.

Authors:  R J Wallace; V A Steingrube; D R Nash; D G Hollis; C Flanagan; B A Brown; A Labidi; R E Weaver
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

6.  Effect of inoculum size on results of macrotube broth dilution susceptibility tests with Branhamella catarrhalis.

Authors:  G V Doern; T Tubert
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

7.  Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis.

Authors:  H J Bootsma; H van Dijk; J Verhoef; A Fleer; F R Mooi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Meningococcal chest infections in a general hospital.

Authors:  B I Davies; L Spanjaard; J Dankert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-05       Impact factor: 3.267

9.  Detection of beta-lactamase activity among clinical isolates of Branhamella catarrhalis with six different beta-lactamase assays.

Authors:  G V Doern; T A Tubert
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

10.  Moraxella catarrhalis expresses a cardiolipin synthase that impacts adherence to human epithelial cells.

Authors:  Sean W Buskirk; Eric R Lafontaine
Journal:  J Bacteriol       Date:  2013-10-18       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.